Activin and Inhibin

HG6-64-1 is a potent and selective B-Raf inhibitor extracted from patent WO 2011090738 A2, example 9 (XI-1): has a IC 50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells.Form:SolidIC50&amp: Target:B-Raf V600E 0.09 μM (IC 50 , in Ba/F3 cells).

HG6-64-1 is a potent and selective B-Raf inhibitor extracted from patent WO 2011090738 A2, example 9 (XI-1): has a IC 50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells.Form:SolidIC50&amp: Target:B-Raf V600E 0.09 μM (IC 50 , in Ba/F3 cells).

HG6-64-1 is a potent and selective B-Raf inhibitor extracted from patent WO 2011090738 A2, example 9 (XI-1): has a IC 50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells.Form:SolidIC50&amp: Target:B-Raf V600E 0.09 μM (IC 50 , in Ba/F3 cells).

HG6-64-1 is a potent and selective B-Raf inhibitor extracted from patent WO 2011090738 A2, example 9 (XI-1): has a IC 50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells.IC50&amp: Target:B-Raf V600E 0.09 μM (IC 50 , in Ba/F3 cells).

HGPR91 antagonist 1 is a potent and selective small molecule hGPR91 antagonist with an IC 50 of 7 μMIn VivoHGPR91 antagonist 1 leads to 59, 76% inhibition of ΔMAP at 2, 4 hours and has shown rat plasma protein binding 99%. HGPR91 antagonist 1 has

HGPR91 antagonist 1 is a potent and selective small molecule hGPR91 antagonist with an IC 50 of 7 μMIn VivoHGPR91 antagonist 1 leads to 59, 76% inhibition of ΔMAP at 2, 4 hours and has shown rat plasma protein binding 99%. HGPR91 antagonist 1 has

HGPR91 antagonist 1 is a potent and selective small molecule hGPR91 antagonist with an IC 50 of 7 μMIn VivoHGPR91 antagonist 1 leads to 59, 76% inhibition of ΔMAP at 2, 4 hours and has shown rat plasma protein binding 99%. HGPR91 antagonist 1 has

HGPR91 antagonist 1 is a potent and selective small molecule hGPR91 antagonist with an IC 50 of 7 μMIn VivoHGPR91 antagonist 1 leads to 59, 76% inhibition of ΔMAP at 2, 4 hours and has shown rat plasma protein binding 99%. HGPR91 antagonist 1 has

HGPR91 antagonist 1 is a potent and selective small molecule hGPR91 antagonist with an IC 50 of 7 μMIn VivoHGPR91 antagonist 1 leads to 59, 76% inhibition of ΔMAP at 2, 4 hours and has shown rat plasma protein binding 99%. HGPR91 antagonist 1 has

HHS-0701, a sulfur-triazole exchange (SuTEx) ligand, is a potent tyrosine-reactive prostaglandin reductase 2 (PTGR2) inhibitor. HHS-0701 blocks PTGR2 metabolism of the lipid substrate 15-Keto-PGE2.In VitroHHS-0701 (0.1, 0.25, 0.5, 1, 2.5, 5, 10, 25

HHS-0701, a sulfur-triazole exchange (SuTEx) ligand, is a potent tyrosine-reactive prostaglandin reductase 2 (PTGR2) inhibitor. HHS-0701 blocks PTGR2 metabolism of the lipid substrate 15-Keto-PGE2.In VitroHHS-0701 (0.1, 0.25, 0.5, 1, 2.5, 5, 10, 25

HHS-0701, a sulfur-triazole exchange (SuTEx) ligand, is a potent tyrosine-reactive prostaglandin reductase 2 (PTGR2) inhibitor. HHS-0701 blocks PTGR2 metabolism of the lipid substrate 15-Keto-PGE2.In VitroHHS-0701 (0.1, 0.25, 0.5, 1, 2.5, 5, 10, 25